Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kronos Bio, Inc. Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations

09/14/2021 | 08:00am EST

Kronos Bio, Inc. announced the appointment of Marni Kottle as senior vice president of Corporate Communications and Investor Relations. Ms. Kottle brings to the role more than two decades of experience in corporate communications and as a journalist covering the biopharmaceutical industry. Prior to Kronos Bio, Ms. Kottle was vice president of Corporate Communications at Gilead Sciences, where she was responsible for the company’s corporate brand, financial communications, media and social media strategies, and employee communications.


ę S&P Capital IQ 2021
All news about KRONOS BIO, INC.
12/06Kronos Bio Says First Patient Dosed in Trial of Leukemia Treatment Entospletinib
MT
12/06KRONOS BIO, INC. : Other Events (form 8-K)
AQ
12/06Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entosplet..
GL
11/29Kronos Bio's Cancer Drug Candidate Shows Potential in Phase 1/2 Trial
MT
11/29KRONOS BIO, INC. : Other Events (form 8-K)
AQ
11/29Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor ..
GL
11/29Kronos Bio, Inc Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhib..
CI
11/24Kronos Bio Announces Participation in Upcoming Investor Conferences
AQ
11/12KRONOS BIO : Management Change/Compensation - Form 8-K/A
PU
11/12KRONOS BIO, INC. Change in Directors or Principal Officers (form 8-K/A)
AQ
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -144 M - -
Net cash 2021 178 M - -
P/E ratio 2021 -4,48x
Yield 2021 -
Capitalization 686 M 686 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 95
Free-Float 83,1%
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 12,17 $
Average target price 43,00 $
Spread / Average Target 253%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-60.33%686
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-42.48%24 298